4-(4-氨基苯氧基)吡啶甲酸叔丁酯 | 1097726-88-9

• 分子结构分类: 有机化合物 - 有机氧化合物
• 中文名称: 4-(4-氨基苯氧基)吡啶甲酸叔丁酯
• 英文名称: tert-butyl 4-(4-aminophenoxy)picolinate
• 英文别名: 4-(4-amino-phenoxy)-pyridine-2-carboxylic acid t-butyl ester；tert-butyl 4-(4-aminophenoxy)pyridine-2-carboxylate
• CAS: 1097726-88-9
• 化学式: C₁₆H₁₈N₂O₃
• 分子量: 286.331
• InChiKey: KCAPIUNPYGHDJX-UHFFFAOYSA-N

物化性质

• 沸点：
  449.6±40.0 °C(Predicted)
• 密度：
  1.178±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.9
• 重原子数：
  21
• 可旋转键数：
  5
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  74.4
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  4-(4-氨基苯氧基)吡啶甲酸叔丁酯 在 三乙基硅烷 、 N,N-二异丙基乙胺 、 Methanaminium,N-[(dimethylamino)(3H-1,2,3-triazolo[4,5-b]pyridin-3-yloxy)methylene]-N-methyl-, hexafluorophosphate(1-) 、 三氟乙酸 作用下， 以 二氯甲烷 、 N,N-二甲基甲酰胺 为溶剂， 反应 48.0h， 生成 索拉非尼-d3
  参考文献：
  名称：

  METHOD AND PROCESS FOR PREPARATION AND PRODUCTION OF DEUTERATED OMEGA-DIPHENYLUREA

  摘要：

  揭示了制备和生产重氮化ω-二苯脲的方法和过程。特别是，揭示了一种可以抑制磷酸激酶的重氮化ω-二苯脲化合物以及N-(4-氯-3-(三氟甲基)苯基-N′-(4-(2-(N-d3-甲基氨基甲酰)-4-吡啶氧基)苯基)尿素的制备方法。所述的重氮化二苯脲化合物可用于治疗或预防肿瘤及相关疾病。

  公开号：

  US20130035492A1
• 作为产物：
  描述：

  4-氯-2-吡啶甲酸 在 吡啶 、 氯化亚砜 、 potassium tert-butylate 作用下， 以 二氯甲烷 、 N,N-二甲基甲酰胺 为溶剂， 反应 20.5h， 生成 4-(4-氨基苯氧基)吡啶甲酸叔丁酯
  参考文献：
  名称：

  METHOD AND PROCESS FOR PREPARATION AND PRODUCTION OF DEUTERATED OMEGA-DIPHENYLUREA

  摘要：

  揭示了制备和生产重氮化ω-二苯脲的方法和过程。特别是，揭示了一种可以抑制磷酸激酶的重氮化ω-二苯脲化合物以及N-(4-氯-3-(三氟甲基)苯基-N′-(4-(2-(N-d3-甲基氨基甲酰)-4-吡啶氧基)苯基)尿素的制备方法。所述的重氮化二苯脲化合物可用于治疗或预防肿瘤及相关疾病。

  公开号：

  US20130035492A1

文献信息

• INTRACELLULAR SUBSTANCE TRANSPORT SYSTEM AND USE THEREOF
  申请人：National University Corporation Hokkaido University

  公开号：US20200138973A1

  公开（公告）日：2020-05-07

  The present invention pertains to a complex including nanoparticles and, carried on the surface of the nanoparticles, a lysosomal enzyme inhibitor or kinase inhibitor shown by general formula (A) and a phospholipid mimetic substance shown by general formula (B). In general formula (A), n1 is an integer of 2-30, n2 is an integer of 2-30, the -S- terminal is a nanoparticle-carrying site, and R10 is a suicide substrate site or a kinase inhibition site. In general formula (B), n3 is an integer in the range of 2-30, and the -S- terminal is a nanoparticle-carrying site. The present invention provides a versatile system capable of efficiently delivering a drug to endolysosomes and allowing the drug to function at a low concentration on lysosomal enzymes, and an anticancer agent in which this system is used.

  本发明涉及一种包括纳米粒子的复合物，所述纳米粒子表面携带有一种由通用式（A）显示的溶酶体酶抑制剂或激酶抑制剂以及一种由通用式（B）显示的磷脂类拟物物质。 在通用式（A）中，n1是2-30的整数，n2是2-30的整数，-S-端是纳米粒子携带位点，R10是自杀底物位点或激酶抑制位点。在通用式（B）中，n3是2-30范围内的整数，-S-端是纳米粒子携带位点。本发明提供了一种多功能系统，能够有效地将药物传递至内溶酶体，并使药物在低浓度下对溶酶体酶起作用，以及使用该系统的抗癌剂。
• [EN] CYCLOPROPANE AMIDES AND ANALOGS EXHIBITING ANTI-CANCER AND ANTI-PROLIFERATIVE ACTIVITIES<br/>[FR] AMIDES DE CYCLOPROPANE ET ANALOGUES PRÉSENTANT DES ACTIVITÉS ANTICANCÉREUSES ET ANTIPROLIFÉRATIVES
  申请人：DECIPHERA PHARMACEUTICALS LLC

  公开号：WO2010051373A1

  公开（公告）日：2010-05-06

  Compounds of the present invention find utility in the treatment of mammalian cancers and especially human cancers including, but not limited to, malignant melanomas, solid tumors, glioblastomas, ovarian cancer, pancreatic cancer, prostate cancer, lung cancers, breast cancers, kidney cancers, hepatic cancers, cervical carcinomas, metastasis of primary tumor sites, myeloproliferative diseases, chronic myelogenous leukemia, leukemias, papillary thyroid carcinoma, non-small cell lung cancer, mesothelioma, hypereosinophilic syndrome, gastrointestinal stromal tumors, colonic cancers, ocular diseases characterized by hyperproliferation leading to blindness including various retinopathies, diabetic retinopathy, rheumatoid arthritis, asthma, chronic obstructive pulmonary disease, mastocytosis, mast cell leukemia, and diseases caused by PDGFR-α kinase, PDGFR-β kinase, c-KIT kinase, cFMS kinase, c-MET kinase, and oncogenic forms, aberrant fusion proteins and polymorphs of any of the foregoing kinases.

  本发明的化合物在治疗哺乳动物癌症，尤其是人类癌症方面具有实用性，包括但不限于恶性黑色素瘤、实体肿瘤、胶质母细胞瘤、卵巢癌、胰腺癌、前列腺癌、肺癌、乳腺癌、肾癌、肝癌、宫颈癌、原发肿瘤部位的转移、骨髓增生性疾病、慢性髓细胞白血病、白血病、乳头状甲状腺癌、非小细胞肺癌、间皮瘤、高嗜酸性综合征、胃肠道间质瘤、结肠癌、由高增殖导致失明的眼部疾病，包括各种视网膜病变、糖尿病视网膜病变、类风湿性关节炎、哮喘、慢性阻塞性肺病、肥大细胞增多症、肥大细胞白血病，以及由PDGFR-α激酶、PDGFR-β激酶、c-KIT激酶、cFMS激酶、c-MET激酶和致癌形式、异常融合蛋白和任何上述激酶的多态体引起的疾病。
• Oximide derivatives and their therapeutical application
  申请人：Yu Chang Jun

  公开号：US20090012091A1

  公开（公告）日：2009-01-08

  The present invention relates to a compound represented as the following Formula (I) and a pharmaceutical composition thereof wherein all substituents are as defined in the specification; and also relates to a method for treating or lessening the severity of a disease or a condition, comprising administering said compound or said pharmaceutical composition.

  本发明涉及一种表示为以下化学式（I）的化合物及其药物组合物，其中所有取代基如规范中定义；还涉及一种治疗或减轻疾病或病况严重程度的方法，包括给予该化合物或该药物组合物。
• Method and process for preparation and production of deuterated Ω-diphenylurea
  申请人：Feng Weidong

  公开号：US08669369B2

  公开（公告）日：2014-03-11

  Methods and processes for preparation and production of deuterated ω-diphenylurea are disclosed. Especially, a kind of deuterated ω-diphenylurea compounds which can inhibit phosphokinase and the preparation method of N-(4-chloro-3-(trifluoromethyl)phenyl)-N′-(4-(2-(N-d3-methylcarbamoyl)-4-pridinyloxy)phenyl)urea are disclosed. The said deuterated diphenylurea compounds can be used for treating or preventing tumors and relative diseases.

  本文介绍了制备和生产氘代ω-二苯基脲的方法和过程。特别地，本文揭示了一种可以抑制磷酸激酶的氘代ω-二苯基脲化合物以及N-(4-氯-3-(三氟甲基)苯基)-N'-(4-(2-(N-d3-甲基氨基甲酰)-4-吡啶氧基)苯基)脲的制备方法。所述的氘代二苯基脲化合物可用于治疗或预防肿瘤及相关疾病。
• CYCLOPROPANE AMIDES AND ANALOGS EXHIBITING ANTI-CANCER AND ANTI-PROLIFERATIVE ACTIVITIES
  申请人：Flynn Daniel L.

  公开号：US20130079362A1

  公开（公告）日：2013-03-28

  Compounds of the present invention find utility in the treatment of mammalian cancers and especially human cancers including, but not limited to, malignant melanomas, solid tumors, glioblastomas, ovarian cancer, pancreatic cancer, prostate cancer, lung cancers, breast cancers, kidney cancers, hepatic cancers, cervical carcinomas, metastasis of primary tumor sites, myeloproliferative diseases, chronic myelogenous leukemia, leukemias, papillary thyroid carcinoma, non-small cell lung cancer, mesothelioma, hypereosinophilia syndrome, gastrointestinal stromal tumors, colonic cancers, ocular diseases characterized by hyperproliferation leading to blindness including various retinopathies, diabetic retinopathy, rheumatoid arthritis, asthma, chronic obstructive pulmonary disease, mastocytosis, mast cell leukemia, and diseases caused by PDGFR-α kinase, PDGFR-β kinase, c-KIT kinase, cFMS kinase, c-MET kinase, and oncogenic forms, aberrant fusion proteins and polymorphs of any of the foregoing kinases.

  本发明化合物可用于治疗哺乳动物癌症，尤其是人类癌症，包括但不限于恶性黑色素瘤、实体肿瘤、胶质母细胞瘤、卵巢癌、胰腺癌、前列腺癌、肺癌、乳腺癌、肾癌、肝癌、宫颈癌、原发性肿瘤部位的转移、骨髓增生性疾病、慢性髓细胞白血病、白血病、乳头状甲状腺癌、非小细胞肺癌、间皮瘤、高嗜酸性综合症、胃肠道间质瘤、结肠癌、眼病（以细胞增殖导致失明），包括各种视网膜病变、糖尿病视网膜病变、类风湿性关节炎、哮喘、慢性阻塞性肺病、肥大细胞病、肥大细胞白血病，以及由PDGFR-α激酶、PDGFR-β激酶、c-KIT激酶、cFMS激酶、c-MET激酶和任何上述激酶的癌变形式、异常融合蛋白和多态形式引起的疾病。